BridgeBio Pharma (BBIO) Stock Forecast & Price Target

$26.34

+0.96 (+3.78%)

(As of 10/16/2024 ET)

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
2

Buy
12

Based on 14 Wall Street analysts who have issued ratings for BridgeBio Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, and 12 have given a buy rating for BBIO.

Consensus Price Target

$47.62
80.77% Upside

According to the 14 analysts' twelve-month price targets for BridgeBio Pharma, the average price target is $47.62. The highest price target for BBIO is $70.00, while the lowest price target for BBIO is $37.00. The average price target represents a forecasted upside of 80.77% from the current price of $26.34.

Get the Latest News and Ratings for BBIO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors.

BBIO Analyst Ratings Over Time

Type	Current Forecast 10/17/23 to 10/16/24	1 Month Ago 9/17/23 to 9/16/24	3 Months Ago 7/19/23 to 7/18/24	1 Year Ago 10/17/22 to 10/17/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$47.62	$47.92	$48.31	$37.30
Forecasted Upside	80.77% Upside	82.96% Upside	86.30% Upside	39.28% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

BBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BridgeBio Pharma Stock vs. The Competition

Type	BridgeBio Pharma	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	88.80% Upside	10,340.51% Upside	6.73% Upside
News Sentiment Rating	Positive News See Recent BBIO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/16/2024	Scotiabank 5 of 5 stars		Initiated Coverage	Sector Outperform	$44.00	+73.36%
10/3/2024	Oppenheimer 3 of 5 stars		Initiated Coverage	Market Perform
9/30/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$43.00 ➝ $43.00	+72.41%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$70.00 ➝ $70.00	+167.18%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00	+40.05%
9/4/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$46.00	+60.06%
Get the Latest News and Ratings for BBIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$46.00 ➝ $43.00	+77.32%
8/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$50.00 ➝ $45.00	+80.65%
5/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$51.00 ➝ $47.00	+68.22%
3/21/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$45.00	+57.18%
3/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$60.00 ➝ $53.00	+63.81%
2/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$42.00 ➝ $46.00	+34.58%
1/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$37.00	+2.52%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$58.00	+72.57%
7/18/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$29.00 ➝ $50.00	+56.05%
7/18/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.00 ➝ $42.00	+31.09%
7/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$24.00 ➝ $33.00	+3.00%
4/13/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$25.00 ➝ $27.00	+77.87%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$23.00 ➝ $19.00	+123.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:27 PM ET.

BBIO Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for BridgeBio Pharma is $47.62, with a high forecast of $70.00 and a low forecast of $37.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BBIO shares.
: According to analysts, BridgeBio Pharma's stock has a predicted upside of 80.77% based on their 12-month stock forecasts.
: BridgeBio Pharma has been rated by research analysts at Bank of America, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Oppenheimer, Piper Sandler, and Scotiabank in the past 90 days.
: Analysts like BridgeBio Pharma more than other "medical" companies. The consensus rating score for BridgeBio Pharma is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how BBIO compares to other companies.